APO Research
Talk to an analyst

APO RESEARCH · REPORT

Topoisomerase I Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Topoisomerase I Inhibitors Market Outlook and Growth Opportunities 2026

21 December 2025200 pages

Choose your research edition.

Industry ResearchTopoisomerase I Inhibitors Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Topoisomerase I Inhibitors Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Topoisomerase I Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Topoisomerase I Inhibitors Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Topoisomerase I Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Topoisomerase I Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Topoisomerase I Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Topoisomerase I Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Topoisomerase I Inhibitors market include Chong Kun Dang Pharmaceutical, Grand Pharmaceutical, Teva Pharmaceutical Industries, CSPC Pharmaceutical, Novartis AG, Kelun Pharmaceutical, Pfizer, Hengrui Pharmaceuticals and Daiichi Sankyo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Topoisomerase I Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Topoisomerase I Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Topoisomerase I Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Topoisomerase I Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Topoisomerase I Inhibitors Segment by Company

Chong Kun Dang Pharmaceutical

Grand Pharmaceutical

Teva Pharmaceutical Industries

CSPC Pharmaceutical

Novartis AG

Kelun Pharmaceutical

Pfizer

Hengrui Pharmaceuticals

Daiichi Sankyo

Yakult Honsha

Summit Medical

Servier Laboratories (Aust)

Nippon Kayaku

MOH Holdings

Meitheal Pharmaceuticals

Les Laboratoires Servier SAS

Ipsen SA

Eton Pharmaceuticals

Topoisomerase I Inhibitors Segment by Type

Camptothecin Derivatives

Non-camptothecin

Topoisomerase I Inhibitors Segment by Application

Hospital

Clinic

Others

Topoisomerase I Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Topoisomerase I Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Topoisomerase I Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Topoisomerase I Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze Topoisomerase I Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topoisomerase I Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Topoisomerase I Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topoisomerase I Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Topoisomerase I Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Topoisomerase I Inhibitors industry.

Chapter 3: Detailed analysis of Topoisomerase I Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Topoisomerase I Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Topoisomerase I Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Topoisomerase I Inhibitors Industry Trends Table 2. Topoisomerase I Inhibitors Industry Drivers Table 3. Topoisomerase I Inhibitors Industry Opportunities and Challenges Table 4. Topoisomerase I Inhibitors Industry Restraints Table 5. Global Topoisomerase I Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Topoisomerase I Inhibitors Revenue Share by Company (2021-2026) Table 7. Global Topoisomerase I Inhibitors Sales Volume by Company (k units) & (2021-2026) Table 8. Global Topoisomerase I Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global Topoisomerase I Inhibitors Average Price (US$/unit) of Company (2021-2026) Table 10. Global Topoisomerase I Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global Topoisomerase I Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global Topoisomerase I Inhibitors Company, Product Type & Application Table 13. Global Topoisomerase I Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Topoisomerase I Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Camptothecin Derivatives Table 18. Significant Companies of Non-camptothecin Table 19. Global Topoisomerase I Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Topoisomerase I Inhibitors Sales Volume by Type (2021-2026) & (k units) Table 21. Global Topoisomerase I Inhibitors Sales Volume by Type (2027-2032) & (k units) Table 22. Global Topoisomerase I Inhibitors Sales Volume Share by Type (2021-2026) Table 23. Global Topoisomerase I Inhibitors Sales Volume Share by Type (2027-2032) Table 24. Global Topoisomerase I Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Topoisomerase I Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Topoisomerase I Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Topoisomerase I Inhibitors Sales Value Share by Type (2021-2026) Table 28. Global Topoisomerase I Inhibitors Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global Topoisomerase I Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Topoisomerase I Inhibitors Sales Volume by Application (2021-2026) & (k units) Table 34. Global Topoisomerase I Inhibitors Sales Volume by Application (2027-2032) & (k units) Table 35. Global Topoisomerase I Inhibitors Sales Volume Share by Application (2021-2026) Table 36. Global Topoisomerase I Inhibitors Sales Volume Share by Application (2027-2032) Table 37. Global Topoisomerase I Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Topoisomerase I Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Topoisomerase I Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Topoisomerase I Inhibitors Sales Value Share by Application (2021-2026) Table 41. Global Topoisomerase I Inhibitors Sales Value Share by Application (2027-2032) Table 42. Global Topoisomerase I Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Topoisomerase I Inhibitors Sales by Region (2021-2026) & (k units) Table 44. Global Topoisomerase I Inhibitors Sales Market Share by Region (2021-2026) Table 45. Global Topoisomerase I Inhibitors Sales by Region (2027-2032) & (k units) Table 46. Global Topoisomerase I Inhibitors Sales Market Share by Region (2027-2032) Table 47. Global Topoisomerase I Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Topoisomerase I Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Topoisomerase I Inhibitors Sales Value Share by Region (2021-2026) Table 50. Global Topoisomerase I Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Topoisomerase I Inhibitors Sales Value Share by Region (2027-2032) Table 52. Global Topoisomerase I Inhibitors Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Topoisomerase I Inhibitors Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Topoisomerase I Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Topoisomerase I Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 57. Global Topoisomerase I Inhibitors Sales Market Share by Country (2021-2026) Table 58. Global Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 59. Global Topoisomerase I Inhibitors Sales Market Share by Country (2027-2032) Table 60. Global Topoisomerase I Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Topoisomerase I Inhibitors Sales Value Market Share by Country (2021-2026) Table 62. Global Topoisomerase I Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Topoisomerase I Inhibitors Sales Value Market Share by Country (2027-2032) Table 64. Chong Kun Dang Pharmaceutical Company Information Table 65. Chong Kun Dang Pharmaceutical Business Overview Table 66. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 68. Chong Kun Dang Pharmaceutical Recent Development Table 69. Grand Pharmaceutical Company Information Table 70. Grand Pharmaceutical Business Overview Table 71. Grand Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 73. Grand Pharmaceutical Recent Development Table 74. Teva Pharmaceutical Industries Company Information Table 75. Teva Pharmaceutical Industries Business Overview Table 76. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio Table 78. Teva Pharmaceutical Industries Recent Development Table 79. CSPC Pharmaceutical Company Information Table 80. CSPC Pharmaceutical Business Overview Table 81. CSPC Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 83. CSPC Pharmaceutical Recent Development Table 84. Novartis AG Company Information Table 85. Novartis AG Business Overview Table 86. Novartis AG Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Novartis AG Topoisomerase I Inhibitors Product Portfolio Table 88. Novartis AG Recent Development Table 89. Kelun Pharmaceutical Company Information Table 90. Kelun Pharmaceutical Business Overview Table 91. Kelun Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 93. Kelun Pharmaceutical Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Pfizer Topoisomerase I Inhibitors Product Portfolio Table 98. Pfizer Recent Development Table 99. Hengrui Pharmaceuticals Company Information Table 100. Hengrui Pharmaceuticals Business Overview Table 101. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 103. Hengrui Pharmaceuticals Recent Development Table 104. Daiichi Sankyo Company Information Table 105. Daiichi Sankyo Business Overview Table 106. Daiichi Sankyo Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio Table 108. Daiichi Sankyo Recent Development Table 109. Yakult Honsha Company Information Table 110. Yakult Honsha Business Overview Table 111. Yakult Honsha Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Yakult Honsha Topoisomerase I Inhibitors Product Portfolio Table 113. Yakult Honsha Recent Development Table 114. Summit Medical Company Information Table 115. Summit Medical Business Overview Table 116. Summit Medical Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Summit Medical Topoisomerase I Inhibitors Product Portfolio Table 118. Summit Medical Recent Development Table 119. Servier Laboratories (Aust) Company Information Table 120. Servier Laboratories (Aust) Business Overview Table 121. Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio Table 123. Servier Laboratories (Aust) Recent Development Table 124. Nippon Kayaku Company Information Table 125. Nippon Kayaku Business Overview Table 126. Nippon Kayaku Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio Table 128. Nippon Kayaku Recent Development Table 129. MOH Holdings Company Information Table 130. MOH Holdings Business Overview Table 131. MOH Holdings Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. MOH Holdings Topoisomerase I Inhibitors Product Portfolio Table 133. MOH Holdings Recent Development Table 134. Meitheal Pharmaceuticals Company Information Table 135. Meitheal Pharmaceuticals Business Overview Table 136. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 138. Meitheal Pharmaceuticals Recent Development Table 139. Les Laboratoires Servier SAS Company Information Table 140. Les Laboratoires Servier SAS Business Overview Table 141. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio Table 143. Les Laboratoires Servier SAS Recent Development Table 144. Ipsen SA Company Information Table 145. Ipsen SA Business Overview Table 146. Ipsen SA Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Ipsen SA Topoisomerase I Inhibitors Product Portfolio Table 148. Ipsen SA Recent Development Table 149. Eton Pharmaceuticals Company Information Table 150. Eton Pharmaceuticals Business Overview Table 151. Eton Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 153. Eton Pharmaceuticals Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Topoisomerase I Inhibitors Distributors List Table 157. Topoisomerase I Inhibitors Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Topoisomerase I Inhibitors Product Image Figure 2. Global Topoisomerase I Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Topoisomerase I Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global Topoisomerase I Inhibitors Sales (2021-2032) & (k units) Figure 5. Global Topoisomerase I Inhibitors Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Topoisomerase I Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Camptothecin Derivatives Image Figure 10. Non-camptothecin Image Figure 11. Global Topoisomerase I Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Topoisomerase I Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Topoisomerase I Inhibitors Sales Volume Share by Type (2021-2032) Figure 14. Global Topoisomerase I Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Topoisomerase I Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Topoisomerase I Inhibitors Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Topoisomerase I Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Topoisomerase I Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Topoisomerase I Inhibitors Sales Volume Share by Application (2021-2032) Figure 23. Global Topoisomerase I Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Topoisomerase I Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Topoisomerase I Inhibitors Sales Value Share by Application (2021-2032) Figure 26. Global Topoisomerase I Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Topoisomerase I Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Topoisomerase I Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Topoisomerase I Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Topoisomerase I Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 31. North America Topoisomerase I Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Topoisomerase I Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Topoisomerase I Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Topoisomerase I Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Topoisomerase I Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Topoisomerase I Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. South America Topoisomerase I Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Topoisomerase I Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Topoisomerase I Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Topoisomerase I Inhibitors Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Topoisomerase I Inhibitors Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Camptothecin Derivatives
  • Non-camptothecin
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chong Kun Dang Pharmaceutical
  • Grand Pharmaceutical
  • Teva Pharmaceutical Industries
  • CSPC Pharmaceutical
  • Novartis AG
  • Kelun Pharmaceutical
  • Pfizer
  • Hengrui Pharmaceuticals
  • Daiichi Sankyo
  • Yakult Honsha
  • Summit Medical
  • Servier Laboratories (Aust)
  • Nippon Kayaku
  • MOH Holdings
  • Meitheal Pharmaceuticals
  • Les Laboratoires Servier SAS
  • Ipsen SA
  • Eton Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Topoisomerase I Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global Topoisomerase I Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global Topoisomerase I Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Topoisomerase I Inhibitors Market Dynamics
  1. 2.1 Topoisomerase I Inhibitors Industry Trends
  2. 2.2 Topoisomerase I Inhibitors Industry Drivers
  3. 2.3 Topoisomerase I Inhibitors Industry Opportunities and Challenges
  4. 2.4 Topoisomerase I Inhibitors Industry Restraints
3 Topoisomerase I Inhibitors Market by Company
  1. 3.1 Global Topoisomerase I Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global Topoisomerase I Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global Topoisomerase I Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global Topoisomerase I Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global Topoisomerase I Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global Topoisomerase I Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global Topoisomerase I Inhibitors Company Product Type and Application
  8. 3.8 Global Topoisomerase I Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Topoisomerase I Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Topoisomerase I Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Topoisomerase I Inhibitors Market by Type
  1. 4.1 Topoisomerase I Inhibitors Type Introduction
  2. 4.1.1 Camptothecin Derivatives
  3. 4.1.2 Non-camptothecin
  4. 4.2 Global Topoisomerase I Inhibitors Sales Volume by Type
  5. 4.2.1 Global Topoisomerase I Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Topoisomerase I Inhibitors Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Topoisomerase I Inhibitors Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Topoisomerase I Inhibitors Sales Value by Type
  9. 4.3.1 Global Topoisomerase I Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Topoisomerase I Inhibitors Sales Value by Type (2021-2032)
  11. 4.3.3 Global Topoisomerase I Inhibitors Sales Value Share by Type (2021-2032)
5 Topoisomerase I Inhibitors Market by Application
  1. 5.1 Topoisomerase I Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Topoisomerase I Inhibitors Sales Volume by Application
  6. 5.2.1 Global Topoisomerase I Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Topoisomerase I Inhibitors Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Topoisomerase I Inhibitors Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Topoisomerase I Inhibitors Sales Value by Application
  10. 5.3.1 Global Topoisomerase I Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Topoisomerase I Inhibitors Sales Value by Application (2021-2032)
  12. 5.3.3 Global Topoisomerase I Inhibitors Sales Value Share by Application (2021-2032)
6 Topoisomerase I Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global Topoisomerase I Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Topoisomerase I Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Topoisomerase I Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global Topoisomerase I Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global Topoisomerase I Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Topoisomerase I Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global Topoisomerase I Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global Topoisomerase I Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global Topoisomerase I Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Topoisomerase I Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America Topoisomerase I Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Topoisomerase I Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe Topoisomerase I Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Topoisomerase I Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Topoisomerase I Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Topoisomerase I Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America Topoisomerase I Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Topoisomerase I Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Topoisomerase I Inhibitors Sales Value Share by Country, 2025 VS 2032
7 Topoisomerase I Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global Topoisomerase I Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Topoisomerase I Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Topoisomerase I Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global Topoisomerase I Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global Topoisomerase I Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global Topoisomerase I Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global Topoisomerase I Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global Topoisomerase I Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Topoisomerase I Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Topoisomerase I Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Topoisomerase I Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chong Kun Dang Pharmaceutical
  2. 8.1.1 Chong Kun Dang Pharmaceutical Company Information
  3. 8.1.2 Chong Kun Dang Pharmaceutical Business Overview
  4. 8.1.3 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  6. 8.1.5 Chong Kun Dang Pharmaceutical Recent Developments
  7. 8.2 Grand Pharmaceutical
  8. 8.2.1 Grand Pharmaceutical Company Information
  9. 8.2.2 Grand Pharmaceutical Business Overview
  10. 8.2.3 Grand Pharmaceutical Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  12. 8.2.5 Grand Pharmaceutical Recent Developments
  13. 8.3 Teva Pharmaceutical Industries
  14. 8.3.1 Teva Pharmaceutical Industries Company Information
  15. 8.3.2 Teva Pharmaceutical Industries Business Overview
  16. 8.3.3 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio
  18. 8.3.5 Teva Pharmaceutical Industries Recent Developments
  19. 8.4 CSPC Pharmaceutical
  20. 8.4.1 CSPC Pharmaceutical Company Information
  21. 8.4.2 CSPC Pharmaceutical Business Overview
  22. 8.4.3 CSPC Pharmaceutical Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  24. 8.4.5 CSPC Pharmaceutical Recent Developments
  25. 8.5 Novartis AG
  26. 8.5.1 Novartis AG Company Information
  27. 8.5.2 Novartis AG Business Overview
  28. 8.5.3 Novartis AG Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis AG Topoisomerase I Inhibitors Product Portfolio
  30. 8.5.5 Novartis AG Recent Developments
  31. 8.6 Kelun Pharmaceutical
  32. 8.6.1 Kelun Pharmaceutical Company Information
  33. 8.6.2 Kelun Pharmaceutical Business Overview
  34. 8.6.3 Kelun Pharmaceutical Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  36. 8.6.5 Kelun Pharmaceutical Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Topoisomerase I Inhibitors Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Hengrui Pharmaceuticals
  44. 8.8.1 Hengrui Pharmaceuticals Company Information
  45. 8.8.2 Hengrui Pharmaceuticals Business Overview
  46. 8.8.3 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  48. 8.8.5 Hengrui Pharmaceuticals Recent Developments
  49. 8.9 Daiichi Sankyo
  50. 8.9.1 Daiichi Sankyo Company Information
  51. 8.9.2 Daiichi Sankyo Business Overview
  52. 8.9.3 Daiichi Sankyo Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio
  54. 8.9.5 Daiichi Sankyo Recent Developments
  55. 8.10 Yakult Honsha
  56. 8.10.1 Yakult Honsha Company Information
  57. 8.10.2 Yakult Honsha Business Overview
  58. 8.10.3 Yakult Honsha Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Yakult Honsha Topoisomerase I Inhibitors Product Portfolio
  60. 8.10.5 Yakult Honsha Recent Developments
  61. 8.11 Summit Medical
  62. 8.11.1 Summit Medical Company Information
  63. 8.11.2 Summit Medical Business Overview
  64. 8.11.3 Summit Medical Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Summit Medical Topoisomerase I Inhibitors Product Portfolio
  66. 8.11.5 Summit Medical Recent Developments
  67. 8.12 Servier Laboratories (Aust)
  68. 8.12.1 Servier Laboratories (Aust) Company Information
  69. 8.12.2 Servier Laboratories (Aust) Business Overview
  70. 8.12.3 Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio
  72. 8.12.5 Servier Laboratories (Aust) Recent Developments
  73. 8.13 Nippon Kayaku
  74. 8.13.1 Nippon Kayaku Company Information
  75. 8.13.2 Nippon Kayaku Business Overview
  76. 8.13.3 Nippon Kayaku Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio
  78. 8.13.5 Nippon Kayaku Recent Developments
  79. 8.14 MOH Holdings
  80. 8.14.1 MOH Holdings Company Information
  81. 8.14.2 MOH Holdings Business Overview
  82. 8.14.3 MOH Holdings Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 MOH Holdings Topoisomerase I Inhibitors Product Portfolio
  84. 8.14.5 MOH Holdings Recent Developments
  85. 8.15 Meitheal Pharmaceuticals
  86. 8.15.1 Meitheal Pharmaceuticals Company Information
  87. 8.15.2 Meitheal Pharmaceuticals Business Overview
  88. 8.15.3 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  90. 8.15.5 Meitheal Pharmaceuticals Recent Developments
  91. 8.16 Les Laboratoires Servier SAS
  92. 8.16.1 Les Laboratoires Servier SAS Company Information
  93. 8.16.2 Les Laboratoires Servier SAS Business Overview
  94. 8.16.3 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio
  96. 8.16.5 Les Laboratoires Servier SAS Recent Developments
  97. 8.17 Ipsen SA
  98. 8.17.1 Ipsen SA Company Information
  99. 8.17.2 Ipsen SA Business Overview
  100. 8.17.3 Ipsen SA Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Ipsen SA Topoisomerase I Inhibitors Product Portfolio
  102. 8.17.5 Ipsen SA Recent Developments
  103. 8.18 Eton Pharmaceuticals
  104. 8.18.1 Eton Pharmaceuticals Company Information
  105. 8.18.2 Eton Pharmaceuticals Business Overview
  106. 8.18.3 Eton Pharmaceuticals Topoisomerase I Inhibitors Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  108. 8.18.5 Eton Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Topoisomerase I Inhibitors Value Chain Analysis
  2. 9.1.1 Topoisomerase I Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Topoisomerase I Inhibitors Sales Mode & Process
  6. 9.2 Topoisomerase I Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Topoisomerase I Inhibitors Distributors
  9. 9.2.3 Topoisomerase I Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst